A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

NCT06754930 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: SHR-1826
DRUG: SHR-1316
DRUG: SHR-9839
DRUG: SHR-8068
DRUG: Ametinib mesylate
DRUG: BP-102
DRUG: Carboplatin

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.